Eupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a hold rating to a strong sell rating in a research note released on Tuesday morning,Zacks.com reports.

Several other equities analysts also recently commented on EPRX. HC Wainwright decreased their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday. Cantor Fitzgerald raised their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Finally, Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.00.

Eupraxia Pharmaceuticals Stock Up 1.2%

EPRX opened at $7.60 on Tuesday. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $9.32. The business has a 50 day moving average of $8.28 and a 200-day moving average of $6.88. The stock has a market cap of $273.30 million, a price-to-earnings ratio of -7.38 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). As a group, analysts expect that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently modified their holdings of EPRX. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $61,000. TCI Wealth Advisors Inc. acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter worth about $65,000. Integrated Wealth Concepts LLC acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter worth about $71,000. Bank of America Corp DE boosted its holdings in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the period. Finally, Guardian Wealth Advisors LLC NC bought a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000.

Eupraxia Pharmaceuticals News Summary

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and an $11.00 price target on EPRX — this provides a clear bullish endorsement that can support the share price. Read More.
• Positive Sentiment: Lifesci Capital maintained a “Strong-Buy” stance on the stock, signaling continued institutional conviction despite model changes. Read More.
• Neutral Sentiment: HC Wainwright published detailed quarterly and multi‑year EPS projections (Q1–Q4 2026 and out-year forecasts through FY2030), giving investors updated guidance to model future cash needs and valuation — useful but not immediately directional. Read More.
• Negative Sentiment: Zacks Research downgraded EPRX from “Hold” to “Strong Sell,” which can pressure sentiment and trigger selling by model-driven funds or cautious retail investors. Read More.
• Negative Sentiment: HC Wainwright significantly cut EPS forecasts across multiple years (notably FY2026–FY2029 and FY2028), worsening near‑term profitability expectations and raising concerns about cash burn or longer timelines to commercialization. That reduction in earnings outlook is a substantive negative for valuation. Read More.
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (from -$0.75 to -$0.88) — a deterioration in near-term forecasts that may offset some of the positive signal from its “Strong-Buy” rating. Read More.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.